Suven Life Sciences · NSE: SUVEN · BSE: 530239
Q4 FY20 results · Jan–Mar 2020
Suven Life Sciences reported revenue from operations of ₹8.66 crore and net loss of ₹25.56 crore for Q4 FY20 (Jan–Mar 2020), on a consolidated basis.
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 8.66 | 0.00 | — | 2.77 | +212.3% |
| Other income | 3.00 | 0.00 | — | 5.86 | −48.8% |
| Total income | 11.66 | 0.00 | — | 8.63 | +35.1% |
| Profit before tax | (23.36) | 0.00 | — | (22.77) | Loss widened |
| Net profit for the period | (25.56) | 0.00 | — | (22.81) | Loss widened |
| EPS, basic (₹) | (2.01) | 0.00 | — | (1.79) | Loss widened |
| Net margin (%) | -295.1 | — | -822.8 |
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 8.66 | 253.30 | −96.6% | 2.77 | +212.3% |
| Other income | 3.00 | 3.75 | −20.1% | 5.86 | −48.8% |
| Total income | 11.66 | 257.05 | −95.5% | 8.63 | +35.1% |
| Profit before tax | (0.36) | 102.01 | Turned loss | (4.46) | Loss narrowed |
| Net profit for the period | (2.56) | 67.98 | Turned loss | (4.50) | Loss narrowed |
| EPS, basic (₹) | (0.20) | 5.34 | Turned loss | (0.35) | Loss narrowed |
| Net margin (%) | -29.6 | 26.8 | -162.4 |
Consolidated
- Filed with BSE
- 06 Jun 2020, 16:08 IST
- Board meeting
- 05 Jun 2020
- Period
- 01 Jan 2020 to 31 Mar 2020
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 06 Jun 2020, 16:08 IST
- Board meeting
- 05 Jun 2020
- Period
- 01 Jan 2020 to 31 Mar 2020
- Review status
- Audited
- Source
- XBRL filing on BSE